clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Abnormalities, Drug-Induced D000014 10 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abscess D000038 13 associated lipids
Achlorhydria D000126 1 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Adenocarcinoma D000230 166 associated lipids
Angina Pectoris D000787 27 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Ishii K et al. Comparative study of pharmacokinetic parameters between clarithromycin and erythromycin stearate in relation to their physicochemical properties. 1998 Drug Dev Ind Pharm pmid:15605442
Highleyman L FDA issues Hismanal warning. Food and Drug Administration. 1998 BETA pmid:11365263
Niang M et al. [Painful nodular lesions]. 1998 Rev Med Interne pmid:9793156
Saika T et al. [A mechanism of clarithromycin resistance in Helicobacter pylori]. 1998 Kansenshogaku Zasshi pmid:9796191
Sevin E et al. Co-detection of Helicobacter pylori and of its resistance to clarithromycin by PCR. 1998 FEMS Microbiol. Lett. pmid:9742711
Hiratsuka T et al. [Severe bronchorrhea accompanying alveolar cell carcinoma: treatment with clarithromycin and inhaled beclomethasone]. 1998 Nihon Kokyuki Gakkai Zasshi pmid:9742869
Torresani C Clarithromycin: a new perspective in rosacea treatment. 1998 Int. J. Dermatol. pmid:9620480
Tsuneoka H et al. [Sensitivity of Helicobacter pylori to amoxicillin and clarythromycin with special reference to eradication therapy]. 1998 Kansenshogaku Zasshi pmid:9621560
Amsden GW et al. Oral cimetidine prolongs clarithromycin absorption. 1998 Antimicrob. Agents Chemother. pmid:9660986
Butt AA Cervical adenitis due to Mycobacterium fortuitum in patients with acquired immunodeficiency syndrome. 1998 Am. J. Med. Sci. pmid:9427575
Sonnenberg A et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. 1998 Arch. Intern. Med. pmid:9570170
Dal Bo' N et al. Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? 1998 J. Gastroenterol. Hepatol. pmid:9570242
Kato S et al. Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. 1998 Helicobacter pmid:9844069
Gisbert JP et al. [Omeprazole plus 2 antibiotics for the eradication of H. pylori, are 5 days of treatment sufficient?]. 1998 Rev Clin Esp pmid:9844453
Ieshiro R et al. [Effect of clarithromycin in extending the life expectancy of patients with non-small-cell lung cancer--the second report]. 1998 Jpn J Antibiot pmid:9597484
Sakamoto M et al. [Efficacy of clarithromycin (CAM) in patients with inoperable non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597485
Teramoto S et al. [Effect of clarithromycin administration on interferon-gamma and interleukin 12 mRNA expression in the tumor tissue of non-small-cell lung cancer]. 1998 Jpn J Antibiot pmid:9597486
Tatsis G et al. Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections. 1998 J. Antimicrob. Chemother. pmid:9579716
Perng CL et al. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. 1998 Dig. Dis. Sci. pmid:9539638
Lilley LL and Guanci R A dangerous combination. 1998 Am J Nurs pmid:9612423
Sheu BS et al. One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy. 1998 J. Formos. Med. Assoc. pmid:9585678
Hasegawa M et al. [In vitro activities of faropenem against clarithromycin resistance Helicobacter pylori isolates]. 1998 Kansenshogaku Zasshi pmid:9585692
Cecchi R and Torelli E Schönlein-Henoch purpura in association with duodenal ulcer and gastric Helicobacter pylori infection. 1998 J. Dermatol. pmid:9714985
Dore MP et al. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. 1998 Clin. Infect. Dis. pmid:9675458
Hashimoto Y [Eradication therapies for Helicobacter pylori]. 1998 Kansenshogaku Zasshi pmid:9695480
Wakasugi H et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. 1998 Clin. Pharmacol. Ther. pmid:9695727
Hsieh PF et al. Molecular mechanisms of clarithromycin resistance in Helicobacter pylori. 1998 J. Formos. Med. Assoc. pmid:9700240
Guerriero SE et al. Two cases of clarithromycin-induced digoxin toxicity. 1997 Sep-Oct Pharmacotherapy pmid:9324195
Anzueto A et al. Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. 1997 Sep-Oct Clin Ther pmid:9385486
Svoboda P et al. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: a randomized controlled trial. 1997 May-Jun Hepatogastroenterology pmid:9222709
Best LM et al. Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. 1997 May-Jun Can. J. Gastroenterol. pmid:9218854
O'Brien B et al. Cost effectiveness of alternative Helicobacter pylori eradication strategies in the management of duodenal ulcer. 1997 May-Jun Can. J. Gastroenterol. pmid:9218858
al-Humayyd MS Pharmacokinetic interactions between erythromycin, clarithromycin, roxithromycin and phenytoin in the rat. 1997 Mar-Apr Chemotherapy pmid:9084915
Grunden JW and Fisher KA Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. 1997 Jul-Aug Ann Pharmacother pmid:9220046
Tartaglione T Treatment of nontuberculous mycobacterial infections: role of clarithromycin and azithromycin. 1997 Jul-Aug Clin Ther pmid:9377608
Mikasa K et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. 1997 Jul-Aug Chemotherapy pmid:9209786
Nawarskas JJ et al. Digoxin toxicity secondary to clarithromycin therapy. 1997 Jul-Aug Ann Pharmacother pmid:9220047
Dautzenberg B et al. A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections. 1997 Jan-Feb Infection pmid:9039532
Kearsley NL et al. Comparison of clarithromycin suspension and amoxycillin syrup for the treatment of children with pharyngitis and/or tonsillitis. 1997 Apr-May Br J Clin Pract pmid:9293051
Gisbert JP et al. [What is the current role of clarithromycin in the eradication of Helicobacter pylori?]. 1997 Rev Esp Enferm Dig pmid:9221019
Matsumoto T et al. Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. 1997 Lancet pmid:9228971
Kadayifçi A et al. Clarithromycin-induced fever in a patient with Helicobacter pylori gastritis. 1997 Ann Pharmacother pmid:9184727
Götz JM et al. Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases. 1997 Gut pmid:9203935
Katari SR et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. 1997 Clin Transplant pmid:9193849
Verhaegen J et al. Impredictable susceptibility for cephalosporins in penicillin resistant Streptococcus pneumoniae. 1997 Acta Clin Belg pmid:9204588
Kim MJ et al. Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment. 1997 Gastroenterology pmid:9207259
Gotoh A et al. Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy. 1997 Microbiol. Immunol. pmid:9087962
Driscoll MS and Tyring SK Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. 1997 J. Am. Acad. Dermatol. pmid:9091495
Gui GP et al. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. 1997 J. Antimicrob. Chemother. pmid:9096189
Chaisson RE et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. 1997 AIDS pmid:9147422
Lazzaroni M et al. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. 1997 Am. J. Gastroenterol. pmid:9128316
Díaz F et al. [Cat-scratch disease. A report of 4 cases and a review of the literature]. 1997 Rev Clin Esp pmid:9102668
Szczebara F et al. Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9105846
Arguedas A et al. Comparative trial of 3 days of azithromycin versus 10 days of clarithromycin in the treatment of children with acute otitis media with effusion. 1997 J Chemother pmid:9106017
Horgen L et al. Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium. 1997 Res. Microbiol. pmid:9765852
Denys A [Theoretical basis for the antibiotic therapy of the upper part of the respiratory system]. 1997 Otolaryngol Pol pmid:9757681
Pendland SL et al. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. 1997 J. Clin. Microbiol. pmid:9350781
Kubas G and Gospodarek T [The use of clarithromycin and amoxycillin in pediatric acute otitis media]. 1997 Otolaryngol Pol pmid:9757683
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Burman WJ et al. A retrospective comparison of clarithromycin versus rifampin in combination treatment for disseminated Mycobacterium avium complex disease in AIDS: clarithromycin decreases transfusion requirements. 1997 Int. J. Tuberc. Lung Dis. pmid:9441082
Brady RC et al. Facial sporotrichoid infection with Mycobacterium marinum. 1997 J. Pediatr. pmid:9042142
Suzuki K et al. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages. 1997 Int. J. Tuberc. Lung Dis. pmid:9441102
Axon AT et al. Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9042977
Gotoh A et al. Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori. 1997 Microbiol. Immunol. pmid:9444328
Labenz J et al. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. 1997 Aliment. Pharmacol. Ther. pmid:9042978
Labenz J et al. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. 1997 Aliment. Pharmacol. Ther. pmid:9042979
Prattichizzo FA et al. [Carditis associated with Mycoplasma pneumoniae infection. Clinical aspects and therapeutic problems]. 1997 Minerva Cardioangiol pmid:9446067
Erah PO et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. 1997 J. Antimicrob. Chemother. pmid:9044021
Genné D et al. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447898
Roche B et al. Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi. 1997 Rev Rhum Engl Ed pmid:9051864
Ridgway GL et al. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. 1997 J. Antimicrob. Chemother. pmid:9484871
Goh KL et al. Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? 1997 Aliment. Pharmacol. Ther. pmid:9663838
Visalli MA et al. Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. 1997 Diagn. Microbiol. Infect. Dis. pmid:9294703
Kolkman JJ et al. Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9663840
Miyaji H et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. 1997 Aliment. Pharmacol. Ther. pmid:9663841
Visalli MA et al. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. 1997 Antimicrob. Agents Chemother. pmid:9303375
Ednie LM et al. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). 1997 Antimicrob. Agents Chemother. pmid:9303406
Buckley MJ et al. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. 1997 Dig. Dis. Sci. pmid:9365144
Misiewicz JJ et al. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. 1997 Gut pmid:9462204
Loo VG et al. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. 1997 J. Antimicrob. Chemother. pmid:9462442
Hoffner SE et al. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. 1997 J. Antimicrob. Chemother. pmid:9462443
Torresani C et al. Clarithromycin versus doxycycline in the treatment of rosacea. 1997 Int. J. Dermatol. pmid:9466207
Tzivras M et al. One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. 1997 Eur J Gastroenterol Hepatol pmid:9471024
Kawasaki M et al. Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. 1997 Am. J. Gastroenterol. pmid:9382064
Adamek RJ et al. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. 1997 Am. J. Gastroenterol. pmid:9382084
Cammarota G et al. Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication. 1997 Ital J Gastroenterol Hepatol pmid:9476192
Hotz J [Reflux disease of the gastrointestinal tract. Acute therapy and long-term care in daily practice. 2. Therapeutic procedure--diagnosis--therapy-diagram]. 1997 Fortschr. Med. pmid:9480263
Thornsberry C et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. 1997 Diagn. Microbiol. Infect. Dis. pmid:9458982
Briant C et al. Pericarditis as a manifestation of Lyme disease. 1997 J Emerg Nurs pmid:9460386
Sousa C et al. [Cholestatic hepatitis probably induced by clarithromycin]. 1997 Gastroenterol. Clin. Biol. pmid:9587506
Barry AL et al. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9405952
Mitsuyama T et al. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. 1997 Int. Arch. Allergy Immunol. pmid:9338603
Ando H et al. [Changes in serum anti-Helicobacter pylori IgG antibody, pepsinogen I, and pepsinogen II after eradication therapy of Helicobacter pylori]. 1997 Nihon Shokakibyo Gakkai Zasshi pmid:9396326
Hirakawa T [Diagnosis and treatment of Helicobacter pylori]. 1997 Nippon Ika Daigaku Zasshi pmid:9283206
Meyer JM et al. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9210696
Chimura T [Measurement of antibody titers to chlamydial infection and effects of levofloxacin in cystic cervicitis and chlamydial infection]. 1997 Jpn J Antibiot pmid:9212369
Lim AG et al. Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. 1997 Aliment. Pharmacol. Ther. pmid:9218079
Laine L et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. 1997 Am. J. Gastroenterol. pmid:9399755
Sekkarie MA Torsades de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. 1997 Am. J. Kidney Dis. pmid:9292575
Akaki T et al. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. 1997 Kekkaku pmid:9293712